TRAIL shows potential cardioprotective activity
- 186 Downloads
Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE-/- diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.
KeywordsDiabetic Mouse Cardiac Fibrosis Diabetic Cardiomyopathy Left Ventricle Mass Cardiac Apoptosis
This work was supported by a grant from “Programma di Ricerca Regione-Università 2007/2009” (Regione Emilia Romagna to P.S.) and from “Ministero dell’Università e della Ricerca Scientifica e Tecnologica” of Italy (to B.F.).